CADTH Canadian drug expert committee recommendation: Lanadelumab (Takhzyro -- shire pharma Canada ULC) indication: for the routine prevention of attacks of hereditary angioedema (HAE) in adolescents and adults
The CADTH Canadian Drug Expert Committee (CDEC) recommends that lanadelumab be reimbursed for routine prevention of attacks of hereditary angioedema (HAE) only if the following conditions are met : Conditions for Reimbursement, iInitiation criteria 1. The patient is at least 12 years of age. 2. The...
| Corporate Authors: | , |
|---|---|
| Format: | eBook |
| Language: | English |
| Published: |
Ottawa (ON)
Canadian Agency for Drugs and Technologies in Health
November 2019, 2019
|
| Edition: | Version 1.1 |
| Series: | CADTH common drug review
|
| Subjects: | |
| Online Access: | |
| Collection: | National Center for Biotechnology Information - Collection details see MPG.ReNa |
| Summary: | The CADTH Canadian Drug Expert Committee (CDEC) recommends that lanadelumab be reimbursed for routine prevention of attacks of hereditary angioedema (HAE) only if the following conditions are met : Conditions for Reimbursement, iInitiation criteria 1. The patient is at least 12 years of age. 2. The diagnosis of HAE type I or II is made by a specialist physician who has experience in the diagnosis of HAE. 3. The patient has experienced at least three HAE attacks within any four-week period before initiating lanadelumab therapy that required the use of an acute injectable treatment |
|---|---|
| Physical Description: | 1 PDF file (10 pages) |